Catalyst Orthoscience Announces $12.3 Million Oversubscribed Financing round to Fuel Company Momentum in Shoulder ArthroplastyCatalyst Orthoscience Announces $12.3 Million Oversubscribed Financing round to Fuel Company Momentum in Shoulder ArthroplastyCatalyst Orthoscience Announces $12.3 Million Oversubscribed Financing round to Fuel Company Momentum in Shoulder ArthroplastyCatalyst Orthoscience Announces $12.3 Million Oversubscribed Financing round to Fuel Company Momentum in Shoulder Arthroplasty
  • Home
  • Patients
    • Archer™ CSR Total Shoulder System
    • Archer™ R1 Reverse Shoulder System
    • Find A Surgeon
    • Patient Testimonials
  • Health Care Professionals
    • Archer™ CSR Total Shoulder System
    • Archer™ R1 Reverse Shoulder System
    • Archer™ 3D Targeting Software
    • HCP Testimonials & Case Studies
    • Technical Briefs
    • Catalyst in the Journals
  • News & Events
    • Events
    • News
    • Technical Briefs
    • Catalyst in the Journals
  • About Us
    • Executive Leadership
    • Board of Directors
    • Careers at Catalyst
  • Contact Us
Catalyst OrthoScience Features Innovative Products, Surgical Leaders And Archer™ 3D Targeting Imaging Software At AAOS
August 31, 2021
Archer™ Shoulder Systems Presented, Catalyst Orthoscience Showcasing Innovative Products at Upcoming Orthopedic Events
December 13, 2021

Catalyst Orthoscience Announces $12.3 Million Oversubscribed Financing round to Fuel Company Momentum in Shoulder Arthroplasty

October 6, 2021

Catalyst OrthoScience has received clearance from the U.S. Food & Drug Administration to market its reverse shoulder system. Catalyst expects to begin a limited user release in the United States in the second quarter of 2021 followed by a commercial launch later in 2021.

View Press Release, October 6, 2021

Funding Will Support Continued Innovations and Market Growth as Demand for Archer™ Shoulder Systems Increases

NAPLES, Fla., Oct. 6, 2021 – Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has raised $12.3 million in an oversubscribed Series D financing round led by River Cities Capital  (River Cities) and Mutual Capital Partners (Mutual Capital).

“This funding round comes at a pivotal time for the Catalyst OrthoScience team,” said Brian K. Hutchison, chairman and CEO of Catalyst. “We are experiencing a significant period of growth, and this funding allows us to enhance our innovative product portfolio with further technological advancements in the shoulder arthroplasty space and expand our team across all areas.”

Catalyst has had an incredible year of growth with product introductions that address preoperative planning and reverse total shoulder arthroplasty – the fastest growing segment of the shoulder arthroplasty market. So far this year, Catalyst has:

  • rebranded its product portfolio with the Archer family name,
  • received FDA 510(k) clearance and began a limited launch for the Archer R1 Reverse Shoulder System and
  • introduced its Archer 3D Targeting imaging software for its current product offerings.

Additionally, the Archer CSR Total Shoulder System, Catalyst’s stemless, ellipsoid anatomic system, has continued rapid adoption and growth. Today, the Archer shoulder systems have been used in more than 3,000 surgeries. The first patients are more than five years post-surgery with excellent clinical results.

“We are happy to support Catalyst’s significant momentum and advancing the efforts in shoulder arthroplasty,” said Carter McNabb, managing director at River Cities and a member of Catalyst’s board of directors.

Dentons US LLP acted as legal advisor for Catalyst in the transaction.

About Catalyst OrthoScience Inc.

Catalyst OrthoScience is disrupting the usual approaches to shoulder replacement surgery.

Founded in 2014 by orthopedic surgeon Steven Goldberg, M.D., the company’s goal is to develop innovative medical solutions that make orthopedic surgery less invasive and more efficient for both surgeons and patients. The company has a growing portfolio of patents and pending patents on its distinctive surgical offerings. Headquartered in Naples, Fla., Catalyst products are available across the U.S. For more information, visit www.CatalystOrtho.com.

About River Cities Capital

River Cities is a growth equity firm building high-potential healthcare companies by leveraging the unique interplay of our segments of focus: medical device, healthcare services and healthcare IT. We are dedicated to investing on the right side of healthcare, growing companies that enable clinicians to improve the delivery of care and the experiences and outcomes for the patients. We seek to be a business partner first and a capital provider second, investing significant human capital to leverage our domain expertise, a network of healthcare thought leaders and deep relationships with health systems assembled over our 27-year history.

With more than $750 million of capital raised and a consistent track record of success, the firm has established itself as a preferred source of growth capital. We are actively seeking new portfolio companies for our $200M Fund VI. For more information, please visit www.rccf.com.

###

Share

Related posts

November 1, 2022

Catalyst Ranked One of the Top Ten Startup Companies in 2022


Read more
September 26, 2022

Hurricane Ian Update


Read more
April 12, 2022

Press Release: Catalyst OrthoScience Announces David Sharp as Vice President of Global Marketing


Read more

® indicates U.S. trademark registration. All trademarks and/or images are the property of their respective owners or holders. © 2020 Catalyst OrthoScience Inc.
All rights reserved.

    Nice to meet you. We use cookies to ensure that we give you the best experience on our website.

    Sounds Good